Chitosan-coated antifungal formulations for nebulisation.
OBJECTIVE
The aim of this study was to produce and characterise amphotericin B (AmB) containing chitosan-coated liposomes, and to determine their delivery from an air-jet nebuliser.


METHODS
Soya phosphatidylcholine : AmB (100 : 1) multilamellar vesicles were generated by dispersing ethanol-based proliposomes with 0.9% sodium chloride or different concentrations of chitosan chloride. These liposomes were compared with vesicles produced by the film hydration method and micelles. AmB loading, particle size, zeta potential and antifungal activity were determined for formulations, which were delivered into a two-stage impinger using a jet nebuliser.


RESULTS
AmB incorporation was highest for liposomes produced from proliposomes and was greatest (approximately 80% loading) in chitosan-coated formulations. Following nebulisation, approximately 60% of the AmB was deposited in the lower stage of the two-stage impinger for liposomal formulations, for which the mean liposome size was reduced. Although AmB loading in deoxycholate micellar formulations was high (99%), a smaller dose of AmB was delivered to the lower stage of the two-stage impinger compared to chitosan-coated liposomes generated from proliposomes. Chitosan-coated and uncoated liposomes loaded with AmB had antifungal activities against Candida albicans and C. tropicalis similar to AmB deoxycholate micelles, with a minimum inhibitory concentration of 0.5 microg/ml.


CONCLUSIONS
This study has demonstrated that chitosan-coated liposomes, prepared by an ethanol-based proliposome method, are a promising carrier system for the delivery of AmB using an air-jet nebuliser, having a high drug-loading that is likely to be effectively delivered to the peripheral airways for the treatment of pulmonary fungal infections.
Albasarah
Yacoub Y
YY
Department of Pharmaceutics, School of Pharmacy, University of London, London, UK.
Somavarapu
Satyanarayana
S
Stapleton
Paul
P
Taylor
Kevin M G
KM
D000280:Administration, Inhalation; D000666:Amphotericin B / Q000008:administration & dosage* / Q000494:pharmacology; D000935:Antifungal Agents / Q000008:administration & dosage* / Q000494:pharmacology; D002175:Candida / Q000187:drug effects*; D002626:Chemistry, Pharmaceutical; D048271:Chitosan; D008081:Liposomes; D008823:Micelles; D008826:Microbial Sensitivity Tests; D009330:Nebulizers and Vaporizers
D000935:Antifungal Agents; D008081:Liposomes; D008823:Micelles; D000666:Amphotericin B; D048271:Chitosan